CCR2-targeting siRNA therapy (Alnylam/MGH/MIT)

N/A

Report date: 2025/03/19 20:00:56
NME

Base Information

Drug NameCCR2-targeting siRNA therapy (Alnylam/MGH/MIT)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionC-C chemokine receptor type 2 antagonists
TargetsC-C chemokine receptor type 2
Therapy Area/IndicationsRejection of organ transplantationInflammationCardiovascular Diseases +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAlnylam Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe General Hospital Corporation D/B/A Massachusetts General HospitalAlnylam Pharmaceuticals IncMassachusetts Institute Of Technology
Active IndicationsN/A
Inactive IndicationsRejection of organ transplantationInflammationCardiovascular Diseases +[4] 

Other Information

ATC CodeN/A
Related LinksN/A